🌿 Folk Prescriptions

According to authoritative national drug research institutions, Chinese scientists discovered a rare medicinal plant—Pearl Grass—in the Qinling Mountains’ Yaowang Mountain area, capable of treating hepatitis B. Its extract exhibits strong anti-hepatitis B virus activity and inhibits liver fibrosis, showing ideal therapeutic effects on both acute and chronic hepatitis B and liver cirrhosis.
The remarkable efficacy of Pearl Grass in treating hepatitis B has attracted global attention from liver disease research institutions, prompting extensive studies. The world-renowned British journal *The Lancet* once reported that Pearl Grass induced hepatitis B surface antigen negativity in 59% of patients, causing a sensation in the international medical community. Nobel laureate Dr. Blumberg praised the herb’s effects highly.
Research institutions including China’s Academy of Military Medical Sciences, China-Japan Friendship Hospital, and Third Military Medical University have successively launched studies on Pearl Grass to explore its mysterious healing properties. Professor Zhao Dongke, a pharmacologist recognized as a “distinguished expert” by the Ministry of Health, led a research team dedicated to Pearl Grass. Through extensive experiments, they confirmed that Pearl Grass growing in the Yaowang Mountain region of Qinling is the most effective species among its genus. Based on the mechanism of “detoxifying and softening the liver, dual-action therapy,” they developed a nationally approved new drug—Pearl Grass Hepatitis B Shukang Capsules—and obtained approval from the National Drug Administration. Their research depth and clinical efficacy rank at the forefront both domestically and internationally, demonstrating superior ability to eliminate hepatitis B virus and prevent liver fibrosis compared to similar products. Finally, Pearl Grass research has moved beyond the laboratory stage: Beijing Ditan Hospital pioneered its clinical application, benefiting millions of hepatitis B patients. The achievement is now being submitted for the 2004 National TCM Scientific and Technological Achievement Promotion Project.
Statistics show that China currently has 120 million hepatitis B patients, over 30 million with liver diseases, nearly 1 million new cases annually, and over 400,000 deaths each year due to liver cirrhosis and liver cancer. Recent data from the Ministry of Health indicate that hepatitis B remains the top-ranked disease in incidence. Due to its poor prognosis and potential to progress to cirrhosis and liver cancer, hepatitis B poses a serious threat to human health, making its prevention and control a priority in China’s infectious disease management.